Experience

Davis Polk advised the representatives of the several underwriters in connection with an SEC-registered offering of €5 billion aggregate principal amount of notes by Medtronic Global…

Davis Polk advised McKesson Corporation on Change Healthcare Inc.’s SEC-registered initial public offering of 49,285,713 shares of its common stock at a price to the public of $13 per…

Davis Polk advised the underwriters in connection with the $35 million SEC-registered follow-on offering of ordinary shares of Gamida Cell Ltd. The ordinary shares are listed on the Nasdaq…

Davis Polk advised the underwriters in connection with the SEC-registered offering by The Medicines Company of 5,227,273 shares of common stock for approximately $172.5 million, which…

Davis Polk advised Notre Dame Intermédica Participações S.A. in connection with the equity offering by Bain Capital, the controlling shareholder of Notre Dame Intermédica, of 60,000,000…

Davis Polk advised the representatives of the several underwriters in connection with the $125 million initial public offering of common stock by Atreca, Inc. The common stock is listed on…

Davis Polk advised the joint book-running managers and representatives of the several underwriters on the $155 million initial public offering by Personalis, Inc. The common stock is listed…

Davis Polk advised the representatives of the underwriters in connection with the $163.3 million initial public offering of 9,074,776 shares of common stock of Stoke Therapeutics, Inc.,…

Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the approximately $128 million follow-on offering by Orchard Therapeutics…

Davis Polk advised the underwriters in connection with an initial public offering of 5,750,000 shares of common stock of IDEAYA Biosciences, Inc. at $10.00 per share (which includes the…